Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Inclusion Criteria:

18 years of age or older
History of biopsy documented prostate cancer (any Gleason score)
Past treatment with prostatectomy with our without salvage prostate/pelvic radiation or primary radiation
If past prostatectomy, pathologic stage no greater than T1-3, N1, M0
PSA recurrence with PSAdt 8 months or less. There is no minimum PSA for prostatectomy patients. For patients treated with primary radiation therapy PSA should be 2.0ng/ml or greater
No evidence of recurrent disease on exam, bone scan, CT/MRI abdomen/pelvis on CXR
Prior ADT allowed if less than 6 months and testosterone recovered to within 50 units of normal range
ECOG Performance status of 0-1
Absolute neutrophil count of 1,500 mm3 or greater
Platelet Count 100,000 mm3 or greater
Total bilirubin within normal limits
HG 8gm/dl or greater
Testosterone within 50 units of normal range
No history of bleeding or thromboses within the last 12 months that required medical intervention

Exclusion Criteria:

History of cancer within 5 years, other than prostate cancer and non-melanoma skin cancer
Medical condition requiring concomitant corticosteroids
Active infection
Prior chemotherapy
Neuropathy requiring medical therapy
Documented local recurrence or metastatic prostate cancer
Inability to comply with study and/or follow-up procedures
Life expectancy of less than 2 years
Current, recent (within 4 weeks of first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study
Inadequately controlled hypertension
Any prior history of hypertensive crisis or hypertensive encephalopathy
NYHA Grade II or greater congestive heart failure
History of myocardial infarction or unstable angina within 12 months prior to study enrollment
History of stroke or transient ischemic attack at any time
Known CNS disease
Significant vascular disease
Symptomatic peripheral vascular disease
Evidence of bleeding diathesis or coagulopathy
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to enrollment
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
Serious, non-healing wound, ulcer, or bone fracture
Proteinuria at screening
Known hypersensitivity to any component of Avastin